Phase 2 study of KDS2010 in obesity patients
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs Tisolagiline (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 17 Dec 2024 New trial record
- 11 Dec 2024 According to a NeuroBiogen Company media release, clinical trial to evaluate the safety and efficacy of KDS2010 in approximately 75 overweight or obese patients currently enrolling in South Korea with a cohort in U.S. to be added in 2025.